Overview

IFN Beta-1b and Ribavirin for Covid-19

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
0
Participant gender:
All
Summary
As of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently available, but existing medication could be repurposed. The investigators therefore propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and ribavirin combination treatment for patients hospitalized for COVID-19 infection.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The University of Hong Kong
Collaborator:
Hospital Authority, Hong Kong
Treatments:
Interferon beta-1b
Interferon-beta
Interferons
Ribavirin
Criteria
Inclusion Criteria:

1. Recruited subjects include all adult patients ≥18 years hospitalized for virologic
confirmed SARS-CoV-2 infection.

2. All subjects give written informed consent. For patients who are critically ill,
requiring ICU, ventilation or confused, informed consent will be obtained from spouse,
next-of-kin or legal guardians.

3. Subjects must be available to complete the study and comply with study procedures.
Willingness to allow for serum samples to be stored beyond the study period, for
potential additional future testing to better characterize immune response.

Exclusion Criteria:

1. Inability to comprehend and to follow all required study procedures.

2. Allergy or severe reactions to the study drugs

3. Patients taking medication that will potentially interact with l interferon beta-1b or
ribavirin

4. Pregnant or lactation women

5. Patients with known history of severe depression

6. Received an experimental agent (vaccine, drug, biologic, device, blood product, or
medication) within 1 month prior to recruitment in this study or expect to receive an
experimental agent during this study.

7. To participate in an unrelated trial during the current clinical trial. Nevertheless,
the patients have the right to withdraw from the current clinical trial to join
another clinical trial.

8. Have a history of alcohol or drug abuse in the last 5 years.

9. Have any condition that the investigator believes may interfere with successful
completion of the study.